114 related articles for article (PubMed ID: 31124110)
1. Preparation of iPSCs for Targeted Proteomic Analysis.
Baud A; Heywood WE; Little D; Gissen P; Mills K
Methods Mol Biol; 2019; 1994():131-139. PubMed ID: 31124110
[TBL] [Abstract][Full Text] [Related]
2. Multiplex High-Throughput Targeted Proteomic Assay To Identify Induced Pluripotent Stem Cells.
Baud A; Wessely F; Mazzacuva F; McCormick J; Camuzeaux S; Heywood WE; Little D; Vowles J; Tuefferd M; Mosaku O; Lako M; Armstrong L; Webber C; Cader MZ; Peeters P; Gissen P; Cowley SA; Mills K
Anal Chem; 2017 Feb; 89(4):2440-2448. PubMed ID: 28192931
[TBL] [Abstract][Full Text] [Related]
3. Role of mass spectrometry-based proteomics in the study of cellular reprogramming and induced pluripotent stem cells.
Benevento M; Munoz J
Expert Rev Proteomics; 2012 Aug; 9(4):379-99. PubMed ID: 22967076
[TBL] [Abstract][Full Text] [Related]
4. Defining pluripotent stem cells through quantitative proteomic analysis.
Reiland S; Salekdeh GH; Krijgsveld J
Expert Rev Proteomics; 2011 Feb; 8(1):29-42. PubMed ID: 21329426
[TBL] [Abstract][Full Text] [Related]
5. Comparative proteomic analysis of human somatic cells, induced pluripotent stem cells, and embryonic stem cells.
Kim SY; Kim MJ; Jung H; Kim WK; Kwon SO; Son MJ; Jang IS; Choi JS; Park SG; Park BC; Han YM; Lee SC; Cho YS; Bae KH
Stem Cells Dev; 2012 May; 21(8):1272-86. PubMed ID: 21787230
[TBL] [Abstract][Full Text] [Related]
6. Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response Signaling.
Requena J; Alvarez-Palomo AB; Codina-Pascual M; Delgado-Morales R; Moran S; Esteller M; Sal M; Juan M; Boronat Barado A; Consiglio A; Bogle OA; Wolvetang E; Ovchinnikov D; Alvarez I; Jaraquemada D; Mezquita-Pla J; Oliva R; Edel MJ
Stem Cells; 2019 Apr; 37(4):476-488. PubMed ID: 30664289
[TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomic analysis of mouse embryonic fibroblasts and induced pluripotent stem cells using 16O/18O labeling.
Huang X; Tian C; Liu M; Wang Y; Tolmachev AV; Sharma S; Yu F; Fu K; Zheng J; Ding SJ
J Proteome Res; 2012 Apr; 11(4):2091-102. PubMed ID: 22375802
[TBL] [Abstract][Full Text] [Related]
8. Combining Patient-Reprogrammed Neural Cells and Proteomics as a Model to Study Psychiatric Disorders.
Zuccoli GS; Martins-de-Souza D; Guest PC; Rehen SK; Nascimento JM
Adv Exp Med Biol; 2017; 974():279-287. PubMed ID: 28353247
[TBL] [Abstract][Full Text] [Related]
9. Systems-Wide Approaches in Induced Pluripotent Stem Cell Models.
Lau E; Paik DT; Wu JC
Annu Rev Pathol; 2019 Jan; 14():395-419. PubMed ID: 30379619
[TBL] [Abstract][Full Text] [Related]
10. A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs).
Shirotani K; Matsuo K; Ohtsuki S; Masuda T; Asai M; Kutoku Y; Ohsawa Y; Sunada Y; Kondo T; Inoue H; Iwata N
J Biochem; 2017 Dec; 162(6):391-394. PubMed ID: 28992104
[TBL] [Abstract][Full Text] [Related]
11. Proteomics in the World of Induced Pluripotent Stem Cells.
Lindoso RS; Kasai-Brunswick TH; Monnerat Cahli G; Collino F; Bastos Carvalho A; Campos de Carvalho AC; Vieyra A
Cells; 2019 Jul; 8(7):. PubMed ID: 31336746
[TBL] [Abstract][Full Text] [Related]
12. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
13. An orthogonal comparison of the proteome of human embryonic stem cells with that of human induced pluripotent stem cells of different genetic background.
Faradonbeh MZ; Gharechahi J; Mollamohammadi S; Pakzad M; Taei A; Rassouli H; Baharvand H; Salekdeh GH
Mol Biosyst; 2012 Jun; 8(6):1833-40. PubMed ID: 22543856
[TBL] [Abstract][Full Text] [Related]
14. Do Induced Pluripotent Stem Cell Characteristics Correlate with Efficient In Vitro Smooth Muscle Cell Differentiation? A Comparison of Three Patient-Derived Induced Pluripotent Stem Cell Lines.
Zhou Y; Kang G; Wen Y; Briggs M; Sebastiano V; Pederson R; Chen B
Stem Cells Dev; 2018 Oct; 27(20):1438-1448. PubMed ID: 30153084
[TBL] [Abstract][Full Text] [Related]
15. Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine.
Skalova S; Svadlakova T; Shaikh Qureshi WM; Dev K; Mokry J
Int J Mol Sci; 2015 Feb; 16(2):4043-67. PubMed ID: 25689424
[TBL] [Abstract][Full Text] [Related]
16. Transgene Reactivation in Induced Pluripotent Stem Cell Derivatives and Reversion to Pluripotency of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.
Galat V; Galat Y; Perepitchka M; Jennings LJ; Iannaccone PM; Hendrix MJ
Stem Cells Dev; 2016 Jul; 25(14):1060-72. PubMed ID: 27193052
[TBL] [Abstract][Full Text] [Related]
17. Evolution of induced pluripotent stem cell technology.
Zhou H; Ding S
Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
[TBL] [Abstract][Full Text] [Related]
18. A new era of disease modeling and drug discovery using induced pluripotent stem cells.
Suh W
Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262
[TBL] [Abstract][Full Text] [Related]
19. Feeder-free culture for mouse induced pluripotent stem cells by using UV/ozone surface-modified substrates.
Kimura Y; Kasai K; Miyata S
Mater Sci Eng C Mater Biol Appl; 2018 Nov; 92():280-286. PubMed ID: 30184752
[TBL] [Abstract][Full Text] [Related]
20. Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells.
Cader Z; Graf M; Burcin M; Mandenius CF; Ross JA
Methods Mol Biol; 2019; 1994():1-14. PubMed ID: 31124100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
